Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Phase 1/2 Studies Set the Stage for Targeted Combos in B-Cell Lymphomas

April 27th 2021

Although chemotherapy is not likely to lose its place in the frontline treatment of patients with B-cell lymphomas, encouraging data from early-phase studies evaluating the use of targeted agents in combination with and without chemotherapy are capturing the interest of investigators in the field.

Options for CAR-T Therapy in the Third-Line Setting

April 27th 2021

A key opinion leader in diffuse large B-cell lymphoma provides a historical perspective on third-line options for CAR T-cell therapy and shares insights on both clinical trial and real-world data.

Unmet Needs in Relapsed/Refractory DLBCL

April 27th 2021

An expert in hematology oncology, Amit Patel, BSc, MBBS, PhD, reviews the unmet needs for patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Approves Loncastuximab Tesirine for Relapsed/Refractory Large B-Cell Lymphoma

April 23rd 2021

The FDA has granted an accelerated approval to loncastuximab tesirine (Zynlonta) for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.

Pivotal Trials Address Pressing Questions With CAR T-Cell Therapy in B-Cell Lymphoma

April 22nd 2021

Nilanjan Ghosh MD, PhD, highlights progress made with CAR T-cell therapies in B-cell lymphoma and some ongoing trials generating interest in the field.

Glofitamab Demonstrates Durable Responses in Relapsed/Refractory B-Cell Lymphoma

April 21st 2021

The novel T-cell–engaging bispecific antibody glofitamab demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive B-cell lymphoma.

Umbralisib Expands the Treatment Landscape for Non-Hodgkin Lymphomas

April 21st 2021

A favorable risk profile and clinically meaningful response rates have made umbralisib a new therapeutic option for patients with heavily pretreated indolent non-Hodgkin lymphomas.

Dr. Matasar on the Design of the CHRONOS-3 Trial Examining Copanlisib/Rituximab in Indolent NHL

April 20th 2021

Matthew J. Matasar, MD, discusses the design of the phase 3 CHRONOS-3 trial in indolent non-Hodgkin lymphoma.

Novel Therapies for R/R Follicular Lymphoma

April 19th 2021

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

CAR T for R/R FL: Treatment Considerations

April 19th 2021

Factors that should be considered when evaluating patients with relapsed/refractory follicular lymphoma for CAR T-cell therapy.

Tazemetostat Displays Promising Preclinical Activity in BTK-Resistant MCL Cell Lines

April 16th 2021

Tazemetostat as a single agent or in combination with zanubrutinib demonstrated antitumor activity in mantle cell lymphoma cell lines with intrinsic resistance to BTK inhibitors, suggesting that the agent could be a promising therapeutic option for patients with primary relapsed/refractory disease.

NK Cell–Targeting Strategies Come Into Their Own

April 16th 2021

Although anticancer therapies that leverage T cells have commanded the most attention in the immuno-oncology era of the past decade, strategies based on natural killer cells have recently emerged as attractive approaches.

Dr. Matasar on the Efficacy of Copanlisib Plus Rituximab in Indolent NHL

April 14th 2021

Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.

FDA Approval Insights: Umbralisib in Marginal Zone Lymphoma and Follicular Lymphoma

April 12th 2021

Dr. Fowler discusses the data that served as the basis for the accelerated approval of umbralisib in marginal zone lymphoma and follicular lymphoma, the implications of the regulatory decision on clinical practice, and potential next steps for the PI3Kδ and CK1ε inhibitor.

CAR T-Cell Therapy for R/R Follicular Lymphoma

April 12th 2021

Implications for adding CAR T-cell therapy to the treatment armamentarium for relapsed/refractory follicular lymphoma in the near future.

ZUMA-5 in R/R Follicular Lymphoma

April 12th 2021

Caron A. Jacobson, MD, MMSc, of Dana-Farber Cancer Institute, comments on current data demonstrated by the ZUMA-5 trial in relapsed/refractory follicular lymphoma and the potential use of CAR T-cell therapy moving forward.

Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma

April 10th 2021

The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.

Dr. Solomon on the Rationale For Liso-Cel in Relapsed/Refractory LBCL

April 7th 2021

Scott R. Solomon, MD, discusses the rationale for examining lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

Dr. Ghosh on the Potential Advantages of Frontline CAR T-Cell Therapy in DLBCL

April 5th 2021

Nilanjan Ghosh, MD, PhD, discusses the potential advantages of moving CAR T-cell therapy into the frontline setting for patients with diffuse large B-cell lymphoma.

Treating Follicular Lymphoma With Early Progression

April 5th 2021

Approaches to sequencing therapy for patients with follicular lymphoma who experience progression of disease within 24 months (POD24).